1	Semantic computational analysis of anticoagulation use in atrial fibrillation from real world
2	data
3	Daniel M. Bean ^{1,2*} , James Teo ³ , Honghan Wu ^{4,5,6} , Ricardo Oliveira ⁷ , Raj Patel ⁸ , Rebecca
4	Bendayan ^{1,9} , Ajay M. Shah ^{10,11} , Richard J. B. Dobson ^{1,2,9,12} , Paul A. Scott ^{10,11*}
5	Author affiliations
6	1. Department of Biostatistics and Health Informatics, Institute of Psychiatry,
7	Psychology and Neuroscience, King's College London, London, U.K.
8	2. Health Data Research UK London, University College London, London, U.K.
9	3. Department of Stroke and Neurology, King's College Hospital NHS Foundation
10	Trust, London, U.K.
11	4. Centre for Medical Informatics, Usher Institute, University of Edinburgh, U.K.
12	5. School of Computer and Software, Nanjing University of Information Science and
13	Technology, Nanjing, China
14	6. Health Data Research UK Scotland, Edinburgh, UK
15	7. Unidade de Doenças Imunomediadas Sistémicas (UDIMS), S. Medicina IV, Hospital
16	Prof. Doutor Fernando Fonseca, Amadora Portugal
17	8. Department of Haematology, King's College Hospital NHS Foundation Trust,
18	London, U.K.
19	9. NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation
20	Trust and King's College London, London, U.K.
21	10. British Heart Foundation Centre, King's College London, London, U.K.
22	11. Department of Cardiology, King's College Hospital NHS Foundation Trust, London,
23	U.K.
24	12. Institute of Health Informatics, University College London, London, U.K.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25

26 *Corresponding authors

27	Email: <u>paulscott3@nhs.net</u> (PAS); <u>daniel.bean@kcl.ac.uk</u> (DMB)
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	

43 Abstract

44	Atrial fibrillation (AF) is the most common arrhythmia and significantly increases stroke risk.
45	This risk is effectively managed by oral anticoagulation. Recent studies using national
46	registry data indicate increased use of anticoagulation resulting from changes in guidelines
47	and the availability of newer drugs.
48	The aim of this study is to develop and validate an open source risk scoring pipeline for free-
49	text electronic health record data using natural language processing.
50	AF patients discharged from 1 st January 2011 to 1 st October 2017 were identified from
51	discharge summaries (N=10,030, 64.6% male, average age 75.3 \pm 12.3 years). A natural
52	language processing pipeline was developed to identify risk factors in clinical text and
53	calculate risk for ischaemic stroke (CHA2DS2-VASc) and bleeding (HAS-BLED). Scores
54	were validated vs two independent experts for 40 patients.
55	Automatic risk scores were in strong agreement with the two independent experts for
56	CHA ₂ DS ₂ -VASc (average kappa 0.78 vs experts, compared to 0.85 between experts).
57	Agreement was lower for HAS-BLED (average kappa 0.54 vs experts, compared to 0.74
58	between experts).
59	In high-risk patients (CHA ₂ DS ₂ -VASc \geq 2) OAC use has increased significantly over the last
60	7 years, driven by the availability of DOACs and the transitioning of patients from AP
61	medication alone to OAC. Factors independently associated with OAC use included
62	components of the CHA2DS2-VASc and HAS-BLED scores as well as discharging specialty
63	and frailty. OAC use was highest in patients discharged under cardiology (69%).
64	Electronic health record text can be used for automatic calculation of clinical risk scores at
65	scale. Open source tools are available today for this task but require further validation.

- 66 Analysis of routinely-collected EHR data can replicate findings from large-scale curated
- 67 registries.
- 68

69 Keywords

70 Natural language processing, electronic health records

71 Abbreviations

- AF = atrial fibrillation
- AP = antiplatelet
- 74 DOAC = direct oral anticoagulant
- $75 \quad EHR = electronic health record$
- 76 NLP = natural language processing
- 77 OAC = oral anticoagulant

78 Introduction

79	Atrial fibrillation (AF) affects 2% of the UK population and significantly increases stroke
80	risk.[1] Although this risk can be substantially reduced by oral anticoagulants (OAC),
81	warfarin has historically been underused in AF. Over the last decade the antithrombotic
82	landscape has changed significantly with: (1) the introduction of direct oral anticoagulants
83	(DOACs), and (2) the updated UK NICE 2014 AF guidelines[2] which introduced the
84	CHA2DS2-VASc[3] and HAS-BLED[4] risk calculators and removed endorsement of the use
85	of antiplatelet agents for stroke prevention. A number of large-scale observational studies
86	have found that rates of OAC use have significantly increased since the introduction of
87	DOACs.[5-8] However, these previous analyses have used structured data, which do not
88	capture the full clinical narrative, and many studies have used registry data which can be
89	costly and time-consuming to collect and may not always accurately reflect real-world
90	practice.

An alternative approach to observational research is the use of Electronic Health Record
(EHRs) data generated as part of routine clinical care.[9] Modern EHRs contain a
combination of structured (e.g. age, sex) and unstructured (e.g. free text, image) data. Whilst
free text is information-dense to a human reader, to be useful for computational analysis it
requires conversion to a structured format. Performing this process manually is very labourintensive. However, given the enormous volume of clinical data contained solely in written
notes[10], extracting this information is critical to realizing the full potential of EHRs.

98 Natural language processing (NLP) uses computer algorithms to identify key elements in
99 everyday language and extract meaning from spoken or written language. NLP can be used to
100 convert unstructured text found in EHRs to structured data. This should allow rapid, low-cost

101	and automated analysis of medical text, including the generation of observational data for							
102	research purposes.							
103	In this study we develop an NLP pipeline to calculate clinical risk scores from free text. We							
104	build upon ou	r existing data pooling, harmonization and information retrieval tool						
105	(CogStack[11	,12]), together with a semantic NLP tool for information extraction						
106	(SemEHR[13,14]). Previous studies have found it is possible to accurately predict CHA2DS2-							
107	VASc using EHR text.[15–17] We build on this work to develop a flexible open source							
108	pipeline and c	calculate additional risk scores. Our specific objectives are to:						
109	a)	Develop and validate an NLP risk scoring pipeline.						
110	b)	Explore trends in antithrombotic medication use for AF including the impact						
111	of the	availability of DOACs and changes in NICE 2014 guidelines.						
112	c)	Quantify the association between antithrombotic medication use and relevant						
113	clinica	al patient-level variables.						

115 Methods

116 Data, materials and code

A subset of the dataset limited to anonymisable information (e.g. only UMLS codes and
demographics) is available on request to researchers with suitable training in information
governance and human confidentiality protocols; contact jamesteo@nhs.net. All code for
calculating risk scores is open-source in GitHub at https://github.com/CogStack/risk-scorebuilder . Source text from patient records used in the study will not be available due to
inability to fully anonymise up to the Information Commissioner Office (ICO) standards.
Risk factor-level data is available as S3 Table.

124

125 **Ethical approval**

This study was performed on anonymised data as a clinical audit for service evaluation. The project was reviewed by the King's College Hospital Information Governance committee chaired by the Caldicott Guardian Professor Alastair Baker (the Caldicott Guardian is the statutory individual responsible for protecting the confidentiality of health and care information in a UK healthcare organisation) and approval was granted in November 2018 with continued oversight. The legal basis of secondary use was analysis for service evaluation, operational performance and clinical audit.

133

134 Cohort selection

We used an open-source retrieval system for unstructured clinical data (CogStack)[11,12] to define a cohort of patients aged \geq 18 with AF admitted to KCH between 01-01-2011 and 01-

10-2017. We searched discharge summaries for adult inpatients discharged alive containing 137 the exact keywords "AF", "PAF", "AFib" or "Atrial Fibrillation". Although the risk of stroke 138 139 and OAC indications in atrial flutter are similar to AF, in clinical practice in the UK many patients with isolated typical flutter undergo flutter ablation after which there is significant 140 141 variation in practice in terms of long-term OAC prescription. For this reason we decided not 142 to include patients with flutter. Patients with missing data such as gender or discharge ward were excluded (N=397). We also excluded patients discharged directly from the emergency 143 department, day units or the clinical decision unit, as these did not constitute an inpatient 144 admission and did not generate the discharge summaries we used to identify discharge 145 medication and diagnosis of AF. 146 147 We further refined our cohort using an NLP pipeline SemEHR[13,14] which generates 148 semantic annotation and can detect negation, temporality (current, historic) and experiencer. 149 150 We excluded patients for which the NLP pipeline detected negation, a hypothetical mention or another experiencer (the mention refers to another individual who is not the patient e.g. 151 family history) for AF. 152 153 We defined a new diagnosis of AF as the first mention of AF in a patient with at least one 154 previous visit and no earlier record of AF or prescription of antithrombotic medication. 155

156

157 CHA2DS2-VASc and HAS-BLED risk score calculation

We used the SemEHR NLP pipeline to annotate clinical documents with Unified Medical
Language System (UMLS) concepts.[18] To calculate CHA₂DS₂-VASc and HAS-BLED risk
scores, we manually mapped each phenotypic component of the score (e.g. stroke) to the

161	closest general term in the Human Phenotype Ontology (HPO)[19] and automatically
162	included all descendent terms in the ontology. All HPO concepts were then mapped
163	automatically to UMLS. Medications were manually mapped to UMLS concepts directly (as
164	they are not present in HPO), and the first child terms are included automatically using
165	UMLS concept relationships. The only factor not included was a labile International
166	Normalised Ratio (INR) in the HAS-BLED score, which is not in HPO and is ambiguous in
167	UMLS, and which is not reliably recorded in the dataset.
168	
169	The result is a mapping of each score component to a list of UMLS concepts, which was
170	manually refined based on manual review of a random sample of 205 patients by a single
171	annotator. The final mapping is available as S1 Table. For each component we then identified
172	matching annotations in medical records using the NLP pipeline and awarded points as
173	defined for each score.
174	
175	For patients with multiple admissions (and the possibility of change in risk scores over time)
176	we used the most recent admission to calculate risk scores.

177

178 Antithrombotic Drug Prescription

179 Antithrombotic prescriptions of OACs (apixaban, rivaroxaban, dabigatran, edoxaban,

180 warfarin) and antiplatelets (AP; aspirin, clopidogrel, dipyridamole, ticagrelor, prasugrel) were

- 181 extracted from free text discharge summaries. This was performed using a custom NLP
- 182 pipeline written in Python and specifically adapted to the KCH record structure. Drug

183 mentions are identified by fuzzy matching and any detected mentions are tested for negation

- 184 using regular expressions. The open source code is available at
- 185 https://github.com/CogStack/OAC-NLP .

186

187 Hospital Frailty Risk Score (HFRS) Calculation

- 188 We calculated the Hospital Frailty Risk Score (HFRS) proposed by Gilbert *et al.* [20] which
- uses ICD-10 diagnostic codes to identify a group of patients at higher risk of adverse
- 190 outcomes. We mapped these ICD-10 codes to UMLS concept unique identifiers (CUI) using
- bio-ontology.[21] We used SemEHR to detect all UMLS concepts in free text and calculate
- the total frailty risk as the sum of concept weights as defined by Gilbert *et al.*.[20]
- 193

194 Validation of AF diagnosis, Antithrombotic drug prescription and

195 NLP risk scores

The diagnosis of AF and antithrombotic drug prescriptions were manually validated on a
random sample of 300 discharge summaries (AF diagnosis) or 200 discharge summaries
(prescription) taken from our cohort. Performance was measured by calculating the precision,
recall and F1 score.

200

CHA₂DS₂-VASc and HAS-BLED risk scores were validated for a sample of 40 patients 201 202 selected at random after stratification by gender and age (this sample does not overlap with the initial sample used to refine the automated scoring). Each patient was manually scored for 203 204 all components of CHA2DS2-VASc and HAS-BLED by two independent expert clinicians 205 according to agreed criteria (see S1 Table). Inter-annotator agreement for the final scores was calculated using a weighted Cohen's kappa. Given the high-dimensional complexity of the 206 HFRS, we did not attempt to validate it and instead compared the score distribution to the 207 208 original findings of Gilbert *et al.* [20]

209

210 Statistical analysis

Categorical variables are expressed as percentages and compared using a chi-squared test. 211 212 Normally distributed continuous variables are expressed as mean+/-standard deviation and 213 compared using Student t test. Skewed continuous variables (length of stay, number of visits, HFRS) are expressed as median (minimum-maximum) and compared using a Kruskal-Wallis 214 H-test. Statistical analyses were performed using the StatsModels and scipy libraries in 215 216 Python. In all analyses a P < 0.05 was considered significant. 217 We evaluated temporal trends in the rates of prescription of antithrombotic drugs for patients 218 at high stroke risk (CHA₂DS₂-VASc \geq 2) using linear regression with quarterly data, 219 220 retaining the last visit per quarter for each patient. 221 222 The association of individual risk score (CHA2DS2-VASc and HAS-BLED) components and 223 other clinical variables with antithrombotic prescription were evaluated in univariate and 224 multivariate analyses. Factors with a significant association (P < 0.05) in univariate analysis 225 were entered into multivariate models. These associations were estimated using odds ratios from logistic regression. Uncontrolled hypertension and concomitant alcohol abuse were not 226 227 included in the models as there were too few positive cases in our validation data. Concomitant drugs increasing bleeding risk were also excluded as this includes antiplatelets 228 which could be prescribed for anticoagulation. 229 230 231

232 **Results**

233 Cohort identification

- 234 We identified 11,260 adult patients admitted to KCH with a diagnosis of AF. After excluding
- 1,230 patients (Fig 1) we were left with a final cohort of 10,030 patients admitted 17,387
- times during the prescribing study period and 151,174 times in total (Table 1).

237

238

Fig 1. Derivation of the study cohort. AF = Atrial fibrillation, NLP = natural language

240 processing.

241

242 Table 1. Baseline characteristics of study cohort.

Factor		Total (n=10030)	Any OAC (n=5287)	Warfarin (n=3328)	DOAC (n=1873)	AP only (n=1902)	No Antithrombotic medication (n=1998)	P-value
Other clinical variables	Age (y)	75.3 ± 12.3	75.1 ± 11.5	74.4 ± 11.1	76.4 ± 12.1	77.5 ± 12.5	74.5 ± 14.3	<0.001
<i>Furtuotes</i>	Frailty (HFRS)	2.5 (0.0-28.1)	2.0 (0.0- 28.1)	1.8 (0.0- 23.0)	3.2 (0.0- 28.1)	3.2 (0.0- 20.5)	3.2 (0.0-28.1)	< 0.001
	LOS (days)	6.5 (0.0- 390.0)	6.2 (0.0- 360.4)	6.2 (0.0- 326.2)	6.2 (0.0- 360.4)	6.4 (0.0- 253.7)	5.8 (0.0-390.0)	0.019
	Previous admissions (n)	7.0 (1.0- 242.0)	8.0 (1.0- 242.0)	7.0 (1.0- 178.0)	9.0 (1.0- 242.0)	6.0 (1.0- 215.0)	8.0 (1.0-189.0)	<0.001
CHA2DS 2-VASc factors	Congestive heart failure	3238 (32.3%)	1992 (37.7%)	1254 (37.7%)	711 (38.0%)	529 (27.8%)	511 (25.6%)	<0.001
<i>J</i>	Diabetes mellitus	5722 (57.0%)	3222 (60.9%)	2044 (61.4%)	1125 (60.1%)	984 (51.7%)	976 (48.9%)	< 0.001
	Female	4351 (43.4%)	2277 (43.1%)	1371 (41.2%)	866 (46.2%)	911 (47.9%)	886 (44.3%)	< 0.001
	Hypertension	6828 (68.1%)	3664 (69.3%)	2226 (66.9%)	1376 (73.5%)	1323 (69.6%)	1256 (62.9%)	< 0.001
	Stroke	4824 (48.1%)	2607 (49.3%)	1528 (45.9%)	1028 (54.9%)	967 (50.8%)	952 (47.6%)	< 0.001
	Vascular disease	3132 (31.2%)	1710 (32.3%)	1082 (32.5%)	600 (32.0%)	562 (29.6%)	429 (21.5%)	< 0.001
	0	156 (1.6%)	58 (1.1%)	29 (0.9%)	29 (1.6%)	22 (1.2%)	72 (3.6%)	

CHA2DS 2-VASc	1	392 (3.9%)	168 (3.2%)	118 (3.5%)	46 (2.5%)	78 (4.1%)	112 (5.6%)	
50010	2	932 (9.3%)	451 (8.5%)	306 (9.2%)	143 (7.6%)	171 (9.0%)	207 (10.4%)	
	3	1405 (14.0%)	707 (13.4%)	482 (14.5%)	214 (11.4%)	227 (11.9%)	312 (15.6%)	
	4	1700 (16.9%)	891 (16.9%)	608 (18.3%)	268 (14.3%)	303 (15.9%)	345 (17.3%)	
	5	1853 (18.5%)	1001 (18.9%)	625 (18.8%)	364 (19.4%)	370 (19.4%)	338 (16.9%)	
	6	1651 (16.5%)	899 (17.0%)	540 (16.2%)	337 (18.0%)	338 (17.8%)	310 (15.5%)	
	7	1138 (11.3%)	628 (11.9%)	350 (10.5%)	269 (14.4%)	249 (13.1%)	180 (9.0%)	
	8	613 (6.1%)	371 (7.0%)	211 (6.3%)	153 (8.2%)	115 (6.0%)	92 (4.6%)	
	9	190 (1.9%)	113 (2.1%)	59 (1.8%)	50 (2.7%)	29 (1.5%)	30 (1.5%)	
	Total	4.7 ± 2.0	4.8 ± 2.0	4.7 ± 1.9	5.0 ± 2.0	4.8 ± 2.0	4.3 ± 2.1	< 0.001
HAS- BLED factors*	Abnormal liver function	532 (5.3%)	240 (4.5%)	150 (4.5%)	89 (4.8%)	97 (5.1%)	176 (8.8%)	< 0.001
Jucions	Abnormal renal function	1706 (17.0%)	937 (17.7%)	539 (16.2%)	380 (20.3%)	307 (16.1%)	355 (17.8%)	<0.001
	Alcohol	75 (0.8%)	75 (1.4%)	26 (0.8%)	47 (2.5%)	0 (0.0%)	0 (0.0%)	< 0.001
	Bleeding	1429 (14.2%)	604 (11.4%)	348 (10.5%)	241 (12.9%)	269 (14.1%)	483 (24.2%)	< 0.001
	Drugs increasing bleed risk	3504 (34.9%)	3504 (66.3%)	2130 (64.0%)	1317 (70.3%)	-	-	-
HAS- BLED score	0	681 (6.8%)	204 (3.9%)	141 (4.2%)	62 (3.3%)	148 (7.8%)	194 (9.7%)	
	1	2716 (27.1%)	1053 (19.9%)	723 (21.7%)	314 (16.8%)	650 (34.2%)	638 (31.9%)	
	2	3528 (35.2%)	1780 (33.7%)	1186 (35.6%)	568 (30.3%)	783 (41.2%)	721 (36.1%)	
	3	2190 (21.8%)	1488 (28.1%)	866 (26.0%)	596 (31.8%)	267 (14.0%)	359 (18.0%)	
	4	763 (7.6%)	618 (11.7%)	338 (10.2%)	267 (14.3%)	53 (2.8%)	79 (4.0%)	
	5	135 (1.4%)	127 (2.4%)	65 (1.9%)	59 (3.1%)	1 (0.1%)	7 (0.3%)	
	6	17 (0.2%)	17 (0.3%)	9 (0.3%)	7 (0.4%)	0 (0.0%)	0 (0.0%)	
	Total	2.0 ± 1.1	2.3 ± 1.1	2.2 ± 1.1	2.5 ± 1.1	1.7 ± 0.9	1.8 ± 1.0	< 0.001

243

Continuous variables are represented as mean \pm *standard deviation or median (min-max),*

categorical variables are represented as n (%). Hospital Frailty Risk Score (HFRS) is 244

calculated according to Gilbert et al.[20]. P-value calculated comparing the mutually-245

exclusive groups Warfarin, DOAC, AP-only, No Antithrombotic medication. Continuous 246

variables tested using a Kruskal-Wallis H-test, categorical variables tested using a Chi-247

- 248 squared test. *uncontrolled hypertension is not shown for HAS-BLED as it was not detected
- 249 for any patients. Stroke is only shown under CHA2DS2-VASc but is a factor for both
- 250 *CHA2DS2-VASc and HAS-BLED.*
- 251

252 Validation of AF diagnosis, Antithrombotic drug prescription and

253 NLP risk scores

- A diagnosis of AF was confirmed in 96% of 300 cases reviewed. Of these, 200 cases were
- 255 manually coded for prescription of any of 10 antithrombotic medications. Five drugs with <5
- 256 positive examples in the validation sample were excluded (edoxaban, dipyridamole,
- 257 prasugrel, dabigatran, ticagrelor) due to the small sample size. The pipeline achieved perfect
- 258 precision and recall for these excluded drugs but the sample size was too small to be
- 259 meaningful. The average performance over the remaining 5 drugs was 95% precision at 97%
- recall (Table 2).
- 261

Table 2. Performance of the drug NLP pipeline in manual validation.

Drug	Accuracy	Precision	Recall	F1	Р	FN	FP	TN	ТР
Warfarin	0.94	0.87	0.97	0.92	69	2	10	121	67
Aspirin	0.96	0.90	0.98	0.94	62	1	7	131	61
Rivaroxaban	1.00	1.00	0.95	0.98	22	1	0	178	21
Clopidogrel	1.00	1.00	0.94	0.97	17	1	0	183	16
Apixaban	1.00	1.00	1.00	1.00	13	0	0	187	13
Average	0.98	0.95	0.97	0.96					

263 Discharge summaries were selected at random (n=200) and manually annotated for the

- 265 positive examples in manual annotation is shown. P = total positive examples in manual
- annotation, FN = false negative, FP = false positive, TN = true negative, TP = true positive.

²⁶⁴ prescription of the 10 drugs detected by the pipeline. Performance for the 5 drugs with > 10

С	c	7
Z	Ο	1

268

- 269 The performance of the automatic NLP scoring procedure was evaluated in 40 patients.
- 270 Overall the agreement between two human expert raters and the algorithm for CHA₂DS₂-
- 271 VASc was high for all pairs, and only slightly higher for the two human raters than for the
- algorithm vs. either expert. HAS-BLED agreement however was lower for all comparisons
- 273 (Table 3 and S2 Table). Total scores and risk factor-level variables are available as S3 Table.
- 274
- Table 3. Inter-rater agreement statistics for CHA₂DS₂-VASc and HAS-BLED risk
 scores.

Score	Rater 1	Rater 2	Kappa (95% CI)
CHA ₂ DS ₂ -VASc	Algorithm	Expert A	0.76 (0.65-0.86)
CHA ₂ DS ₂ -VASc	Algorithm	Expert B	0.80 (0.68-0.92)
CHA ₂ DS ₂ -VASc	Expert A	Expert B	0.85 (0.73-0.97)
HAS-BLED	Algorithm	Expert A	0.54 (0.36-0.72)
HAS-BLED	Algorithm	Expert B	0.53 (0.34-0.72)
HAS-BLED	Expert A	Expert B	0.74 (0.51-0.97)

277 Raters 1 and 2 are two independent clinician raters, Algorithm is the automatic scoring

278 *pipeline developed in this paper.*

279

280 Temporal Trends in Antithrombotic drug prescription

- Prior to 2013, OAC use varied between 40-45% (mean 43.4%) with no strong trend (linear
- regression $R^2=0.08$, slope = +0.2% per quarter, Fig 2a,b). From 2013 onwards the average
- 283 OAC rate remained above 47% and there was a gradual increase in OAC use such that at the
- end of the study period 68.4% of patients were taking an OAC (linear regression $R^2=0.77$,
- slope = +1.2% per quarter). This increase in OAC rate is particularly pronounced from 2016
- onwards (linear regression $R^2=0.86$, slope = +2.7% per quarter). Conversely, the proportion

287	of patients taking an AP drug alone declined significantly from 48.9% at the start to 14.5% at
288	the end of the study, with a consistent linear decrease over the period (linear regression
289	$R^2=0.94$, slope = -1.24% per quarter).

290

291 Fig 2. Antithrombotic drug prescribing patterns in the AF cohort patients with

292 CHA₂DS₂-VASc \geq 2. A,B) Prescribing rates for all admissions during the study period. A)

293 OAC choice vs. no OAC. B) Prescribing of OAC and/or AP vs. neither. C) Prescribing rates

stratified by CHA₂DS₂-VASc for all patients. D) Prescribing rates grouped by HFRS as

defined by Gilbert et al. Due to low numbers of patients with score > 20 the final (highest)

bin is wider than the others. E) Prescribing rate vs. age at discharge. Points are the mean

prescribing rate per year for all ages with ≥ 10 patients, a 10-year moving median (trend) is

shown as a dashed red line. F) prescribing rates in patients grouped by discharging specialty.

In C, D, F the number above each bar indicates the number of patients. AP = antiplatelet,

300 HFRS = hospital frailty risk score, OAC = oral anticoagulant.

301

302

At the start of the study warfarin was the only widely available OAC. In 2012 NICE endorsed the use of the first 2 DOACs (Dabigatran and Rivaroxaban) and the prescription of both drugs increased from the end of 2012, at a similar time to when overall OAC use began to rise. From then on there was a gradual increase in the use of DOACs at the expense of warfarin, such that at the end of the study period in 2017 warfarin only contributed a third of all OAC prescriptions.

309

For newly diagnosed AF (n=4986) Antithrombotic drug trends closely mirrored those found
in the overall AF cohort (Fig 3).

312	
313	Fig 3. Prescribing trends for new AF cases over the study period. The solid blue line
314	represents warfarin, the solid pink line represents DOAC, the dashed black line represents AP
315	prescription without any OAC, the solid green line represents the no drug group. Total N =
316	4986. AP = antiplatelet, DOAC = direct oral anticoagulant, OAC = oral anticoagulant.
317	
318	Clinical Factors associated with Antithrombotic drug
319	prescription
320	There was gradual increase in rates of OAC use with a higher CHA ₂ DS ₂ -VASc score (+1.6%
321	per point, linear regression $R^2 = 0.93$, p < 0.001) (Fig 2c). Conversely OAC prescription
322	decreased with older age in patients ≥ 80 years (Fig 2e).
323	
324	In multivariate analysis (Table 4) clinical variables associated with a higher rate of OAC use
325	(vs. no OAC) included heart failure, diabetes and stroke. Factors negatively associated with
326	OAC use included a history of vascular disease, abnormal liver function and history of
327	bleeding. Older patients receiving OAC were more likely to be on warfarin vs. DOACs.
328	Higher rates of AP drug use alone (vs. OAC) were associated with the presence of vascular
329	disease, whereas heart failure, and diabetes were associated with lower rates.
330	
331 332 333	Table 4. Univariate and multivariate logistic regression for factors associated with antithrombotic drug prescribing at most recent discharge for patients with CHA2DS2-VASc \geq 2.

		Any OAC vs no OAC			DOAC vs Warfarin				AP-only vs OAC-only				
		Univari	iate	Multiva	riate	Univar	iate	Multiva	riate	Univar	iate	Multiva	riate
Group	Factor	OR (95%C I)	P- val ue	OR (95%C I)	P- val ue	OR (95%C I)	P- val ue	OR (95%C I)	P- val ue	OR (95%C I)	P- val ue	OR (95%C I)	P- val ue

Other clinical variabl	Age (per 20 years)	0.9 (0.9- 1.0)	0.0 39	0.9 (0.8- 0.9)	<0. 001	1.3 (1.2- 1.4)	<0. 001	0.8 (0.8- 0.9)	<0. 001	1.4 (1.2- 1.5)	<0. 001	1.0 (1.0- 1.1)	0.0 80
23	LOS (per 14 days)	0.9 (0.9- 1.0)	<0. 001	1.0 (0.9- 1.0)	0.0 16	1.1 (1.1- 1.2)	<0. 001	1.1 (1.0- 1.1)	0.0 25	1.1 (1.0- 1.1)	0.0 06	1.0 (1.0- 1.1)	0.0 73
	Visits (per 10)	1.1 (1.0- 1.1)	<0. 001	1.1 (1.1- 1.1)	<0. 001	1.1 (1.1- 1.1)	<0. 001	1.0 (1.0- 1.1)	0.4 46	0.9 (0.9- 1.0)	<0. 001	0.9 (0.9- 1.0)	<0. 001
CHA2 DS2- VASc factors	Congesti ve heart failure	1.7 (1.6- 1.8)	<0. 001	1.7 (1.5- 1.8)	<0. 001	1.0 (0.9- 1.1)	0.8 99			0.7 (0.6- 0.8)	<0. 001	0.7 (0.6- 0.8)	<0. 001
Juciors	Diabetes mellitus	1.4 (1.3- 1.5)	<0. 001	1.2 (1.1- 1.3)	<0. 001	1.0 (0.9- 1.1)	0.9 73			0.8 (0.7- 0.9)	<0. 001	0.9 (0.8- 1.0)	0.0 33
	Female	1.0 (0.9- 1.0)	0.3 27			1.2 (1.1- 1.4)	0.0 02	1.1 (1.0- 1.2)	0.1 69	1.1 (1.0- 1.2)	0.2 21		
	Hyperte nsion	1.1 (1.0- 1.2)	0.0 42	1.1 (1.0- 1.2)	0.1 37	1.4 (1.2- 1.5)	<0. 001	1.1 (0.9- 1.2)	0.2 54	1.1 (1.0- 1.2)	0.0 89		
	Stroke	1.1 (1.0- 1.2)	0.0 20	1.3 (1.1- 1.4)	<0. 001	1.4 (1.3- 1.6)	<0. 001	1.0 (0.9- 1.2)	0.6 69	1.0 (0.9- 1.1)	0.5 51		
	Vascula r disease	1.1 (1.0- 1.2)	0.0 18	0.9 (0.8- 0.9)	0.0 03	1.0 (0.9- 1.1)	0.6 85			1.3 (1.1- 1.5)	<0. 001	1.6 (1.4- 1.9)	<0. 001
HAS- BLED factors	Abnorm al liver function	0.7 (0.6- 0.9)	<0. 001	0.7 (0.5- 0.8)	<0. 001	1.0 (0.8- 1.3)	0.9 52			1.1 (0.8- 1.4)	0.5 59		
	Abnorm al renal function	1.1 (1.0- 1.2)	0.1 36			1.3 (1.1- 1.5)	0.0 02	1.0 (0.8- 1.1)	0.5 94	0.9 (0.8- 1.0)	0.1 17		
	Bleeding	0.6 (0.5- 0.7)	<0. 001	0.6 (0.5- 0.6)	<0. 001	1.3 (1.1- 1.5)	0.0 14	0.9 (0.8- 1.2)	0.6 20	1.2 (1.0- 1.4)	0.0 81		
Frailty	HFRS (per 10 points)	0.8 (0.7- 0.9)	<0. 001	0.7 (0.6- 0.8)	<0. 001	2.6 (2.2- 3.0)	<0. 001	2.1 (1.8- 2.6)	<0. 001	1.2 (1.0- 1.4)	0.0 15	1.2 (1.0- 1.4)	0.0 41
Discha rge Locatio n	Stroke	0.6 (0.6- 0.7)	<0. 001	(referen ce)		1.4 (1.1- 1.6)	<0. 001	(referen ce)		2.2 (1.9- 2.5)	<0. 001	(referen ce)	
	Cardiolo gy	2.2 (2.0- 2.5)	<0. 001	2.6 (2.2- 3.0)	<0. 001	0.7 (0.6- 0.8)	<0. 001	0.5 (0.4- 0.7)	<0. 001	0.3 (0.3- 0.4)	<0. 001	0.2 (0.2- 0.3)	<0. 001
	Elderly Care	0.8 (0.7- 0.9)	<0. 001	1.2 (1.0- 1.4)	0.0 36	1.9 (1.6- 2.2)	<0. 001	0.8 (0.7- 1.1)	0.2 34	1.2 (1.0- 1.4)	0.0 13	0.6 (0.5- 0.7)	<0. 001
	Other medical specialti es	0.8 (0.8- 0.9)	<0. 001	1.2 (1.0- 1.4)	0.0 13	1.2 (1.0- 1.3)	0.0 23	0.7 (0.5- 0.8)	<0. 001	1.0 (0.9- 1.1)	0.9 05	0.6 (0.5- 0.7)	<0. 001
	Surgery & Trauma	1.2 (1.1- 1.3)	<0. 001	1.6 (1.4- 1.8)	<0. 001	0.7 (0.6- 0.8)	<0. 001	0.5 (0.4- 0.6)	<0. 001	0.8 (0.7- 1.0)	0.0 13	0.5 (0.4- 0.5)	<0. 001

All factors significant at p<0.05 *level in univariate analysis were included in the multivariate model. HFRS = hospital frailty risk score, LOS = length of stay*

336

337

338 Hospital Frailty Risk Score (HFRS) and antithrombotic

339 prescription

340 As HFRS increased, OAC use did not significantly change but there was a clear decrease in 341 AP drug use either alone or with an OAC (-8.3% per group, linear regression $R^2 = 0.85$, p <

342 0.01, Fig 2d). However in multivariate analysis increasing HFRS was strongly negatively

343 associated with OAC use, positively associated with DOAC use and positively associated

344 with AP drug use only.

345

346 Relationship Between Discharging Specialty and OAC use

347 We found a large variation in OAC prescribing rates between different specialities (Fig 2f).

348 The highest rate of OAC use was in patients discharged from cardiology (68.8%, n=1048),

349 with lower rates of OAC use in patients discharged under a surgical team (56.6%, n=2768), a

medical specialty (52.3%, n=3196), elderly care (46.8%, n=1249) and the stroke unit (42.0%,

n=1222). The relationship between discharge location and antithrombotic drug use remained

352 significant after correction for a range of clinical variables, age and HFRS (Table 4).

353

354 Medication switching in AF patients

We identified a group of 1708 patients (CHA_2DS_2 -VASc ≥ 2) with 2 or more admissions at

least 12 months apart. Of these 895 (52.4%) changed their antithrombotic medication status

357 (Fig 4a). Overall there was an increase in OAC use from 985 to 1069 patients (+8.5%) and a

at movement of patients to DOACs from warfarin and AP drugs. These findings were more

- 359 marked when only patients whose admissions straddled the 2014 NICE guidelines update
- 360 were included (1096 patients; Fig 4b).
- 361
- **Fig 4. Medication switching in patients with CHA_2DS_2-VASc \geq 2 at last visit. a) all visits**
- at least 12 months apart and b) last visit before vs last visit after the 2014 NICE guideline
- 364 update (b is a subset of a). Line width indicates overall proportion.

365

367 **Discussion**

We have developed a pipeline to calculate clinical risk scores from free-text using NLP. 368 369 Using this pipeline, we were able to estimate CHA₂DS₂-VASc and HAS-BLED risk scores 370 from free-text EHR data that are in line with those calculated manually and could scale up to 371 analyse data on over 10,000 AF patients managed at a multi-site large UK NHS Trust. 372 373 We were able to replicate the changes in antithrombotic drug practices observed over the last 374 7 years in previous registry-based observational studies. First, there has been a substantial 375 increase in the proportion of AF patients at high risk of stroke (CHA₂DS₂-VASc \geq 2) prescribed an OAC, with OAC use rising from 42% in 2011 to 62% in 2017. Second, there 376 has been a reduction in the use of warfarin and an increase in DOAC prescription, such that 377 in 2017 more patients were discharged on a DOAC than warfarin. Third, the use of AP drugs 378 alone to prevent stroke has dropped significantly, from 40% in 2011 to 10% in 2017. 379

380

381 Semantic NLP analysis of routinely-generated clinical data

Clinical applications of NLP are an active research area. A recent systematic review 382 identified 71 NLP applications for clinical text, 12 of which are open-source.[22] We took 383 different approaches to NLP for the two major components of our study: extracting 384 medication from discharge summaries and detecting clinical concepts in text (to derive risk 385 386 scores). For medications, we use a series of regular expression rules tuned to the specific prescription text used in this study with high precision but less generalizability. For risk 387 scoring, we built a concept mapping pipeline on top of an open-source clinical NLP tool 388 SemEHR[13], which can detect far more concepts than it is feasible to manually code rules 389

390 for, but with the trade-off that it is not specifically designed for any particular disease

391 concepts.

392

393 Use of EHR data for retrospective and prospective applications in

394 cardiology

EHRs have been increasingly used to support observational studies. However, typically this
involves the transcription of clinical data from EHRs into a registry-specific electronic case
report form, an approach with many of the limitations inherent of a classical observational
study. The development and maintenance of case registries is time-consuming, and the scope

of the research questions that can be answered are limited to the dataset defined *a priori*. By

400 using a domain-agnostic concept mapping pipeline (SemEHR) on unstructured text, our study

401 was able to test both conventional risk scores (CHA₂DS₂-VASc) and a novel risk score

402 (HFRS).

403

399

Ours is not the first study to utilize unstructured EHR data in AF research.[15–17,23] Our
study builds on this previous work through the use of text data with an NLP pipeline, the
calculation of additional risk scores and an analysis of prescribing patterns. Whilst we
evaluate our pipeline in the context of AF, our aim is to provide an open tool for clinical risk
scoring calculations in general.

409

410 Trends in Antithrombotic drug use

411 Large retrospective population-based studies have established a clear trend of increased OAC412 prescribing in AF patients, driven by uptake of DOACs.[6,7] Our ability to reproduce these

413	findings by applying NLP to unstructured EHR data strongly supports the validity of the NLP
414	pipeline. In our analysis, OAC prescription was independently associated with risk factors for
415	stroke and bleeding, consistent with the findings of other studies.

416

Despite a significant increase in OAC use during our study period, ~35% of patients at high
risk of stroke were still not prescribed an OAC indicating there are some remaining barriers
to OAC use. In our data, a documented bleeding problem (present in 14% of the cohort and
associated with 40% reduction in OAC use) and increasing frailty (Table 4) were independent
predictors of OAC underuse, suggesting that perceived risk of bleeding and risk of harm due
to OAC continues, particularly in elderly patients, to have a strong influence on the

423 antithrombotic drug decision-making process.[24–26]

424

HFRS proposed by Gilbert et al. [20] is a high-dimensional frailty score calculated from 425 ICD-10 diagnostic codes. When we evaluated antithrombotic drug prescription using HFRS 426 as a continuous variable and adjusting for other clinical variables and discharging specialty, 427 there was a significant relationship between HFRS and antithrombotic drug use (Table 4). 428 429 Patients with a higher HFRS were less likely to take an OAC, more likely to take a DOAC (vs. warfarin) if they were on an OAC, and more likely to take an AP drug alone versus an 430 OAC. This suggests there is an underlying high-dimensional frailty characteristic influencing 431 432 clinician decision-making despite not being explicitly calculated.

433

434 The highest OAC prescription rates were in patients discharged from a cardiology ward

435 (n=1048, 69%), whereas OAC use was significantly lower in patients discharged from an

436 elderly care ward (n=1240, 47%) and other medical specialties (n=3196, 52%). Although in

437 part this may reflect the differing case mix of specialty patient populations, given the

magnitude of the differences seen even with multivariate correction of clinical variables
(including stroke and bleed risk factors and frailty risk score), it is likely that some of our
findings are due to specialty-specific behaviours in relation to AF and bleeding risk. This
suggests efforts to continue to increase OAC prescribing rates beyond current may be most
effective if targeted by clinical specialty.

443

444 Limitations

445 One of the major limitations of an EHR- and NLP-based approach, as used in our analysis, is data accuracy. We manually validated the major variables in our analysis but the accuracy of 446 our NLP algorithm deserves closer scrutiny as there is a risk of causing a significant 447 degradation in data accuracy. Whilst the agreement between our algorithm and clinical 448 experts was high for CHA2DS2-VASc and fair for HAS-BLED, in all comparisons the 449 450 agreement between experts was higher. This gap represents room for improvement in the algorithm primarily due to difficulty detecting some risk factors. 451 452 Retrospective assessment of the data source of many of the variables in the HAS-BLED score 453 is challenging irrespective of the approach used, with a previous study finding that inter-rater 454 reliability between human observers for some HAS-BLED components is low.[15] This 455 456 disagreement at the level of the data source is commonly described even with curated registry data.[27] This limitation particularly affected the "uncontrolled hypertension" and "labile 457 INR" features of the HAS-BLED score, neither of which is reliably recorded or detected. 458 This leaves some comorbidity associated with bleeding risk unaccounted for in our 459 460 multivariate analysis.

461

462	Unlike the use of registry data, routine EHR data may not capture all necessary clinical
463	information on all patients, as this is a secondary use of the record. It is therefore possible
464	that we have missed important co-morbidities in some of the patients. This may have led to
465	an overall underestimation of co-morbidities in our patient population, as well as undermined
466	some of our analyses relating clinical variables to anti-thrombotic drug use.
467	
468	The NLP algorithm was tested on data from one multi-site organization using three different
469	EHR systems over a 6-year period. While this may show a degree of generalizability, further
470	validation on data from other EHR systems in other organizations will be needed.
471	
472	We used data from inpatient admissions as these more accurately record data on drug
473	prescriptions. As a result our patient population has the potential to be older and frailer, with
474	more comorbidity, than typical community AF cohorts. Although our population had similar
475	baseline characteristics to the populations in previous studies[28,29], not all co-morbidities
476	may be captured. This is a limitation is inherent in the design of all studies using routinely
477	generated non-curated data.
478	
479	Our study did not attempt to distinguish between the different temporal patterns of atrial
480	fibrillation (permanent, persistent, paroxysmal). This is because these temporal patterns are
481	frequently not used in free text or used ambiguously (e.g. 'PAF' could mean any of the
482	terms). Nonetheless, national and international guidelines on anticoagulation for AF do not
483	have different anticoagulation recommendations for different temporal patterns.
484	

Finally, our data is observational. Therefore, although we have demonstrated associations
between changes in antithrombotic drug use and a range of clinical variables, it is not
possible to conclude a causal link.

488

489 Conclusion

We present a novel open-source methodology for an automated pipeline to calculate risk 490 scores from NLP and track prescribing patterns, incorporating future disease entities, risk 491 492 profiles and ontologies. We have used this methodology to demonstrate significant changes in antithrombotic practice in AF since the introduction of DOACs, in a large NHS Trust. The 493 tools used in this study are open-source and transparent (CogStack[12], SemEHR[14] and our 494 pipeline) allowing any other organization to validate on their own cohorts and optimize local 495 population health at low cost. This highlights the power of semantic NLP processing tools for 496 497 a disease-specific domain, but is generalizable to a variety of other diseases and use-cases, 498 and highlights the growing impact of health informatics in healthcare.[30]

499

500 Acknowledgements

501 DMB is funded by a UKRI Innovation Fellowship as part of Health Data Research UK

502 MR/S00310X/1 (https://www.hdruk.ac.uk). HW is funded by a UKRI Rutherford Fellowship

as part of Health Data Research UK MR/S004149/1. RB is funded in part by grant

504 MR/R016372/1 for the King's College London MRC Skills Development Fellowship

505 programme funded by the UK Medical Research Council (MRC, https://mrc.ukri.org) and by

- 506 grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR,
- 507 https://www.nihr.ac.uk) Biomedical Research Centre at South London and Maudsley NHS

508	Foundation Trust and King's College London. AMS is supported by the British Heart
509	Foundation (https://www.bhf.org.uk). NIHR Biomedical Research Centre funding to
510	SLAM/KCL and to GSTT/KCL in partnership with KCL. The BigData@Heart Consortium is
511	funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No.
512	116074 (https://www.imi.europa.eu). This Joint Undertaking receives support from the
513	European Union's Horizon 2020 research and innovation programme and EFPIA; it is
514	chaired, by DE Grobbee and SD Anker, partnering with 20 academic and industry partners
515	and ESC. This paper represents independent research part funded by the National Institute for
516	Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS
517	Foundation Trust and King's College London. The views expressed are those of the author(s)
518	and not necessarily those of the NHS, the NIHR or the Department of Health and Social
519	Care. The funders had no role in study design, data collection and analysis, decision to
520	publish, or preparation of the manuscript.

521

522 **Competing Interests**

523 I have read the journal's policy and the authors of this manuscript have the following

524 competing interests: Dr. Teo reports non-financial support from Bayer, grants from Bristol-

525 Meyers-Squibb, outside the submitted work; Dr. scott reports personal fees from Bayer,

526 outside the submitted work. All other authors declare that no competing interests exist. This

527 does not alter our adherence to PLOS ONE policies on sharing data and materials.

529 **References**

530	1.	Yiin GSC, Howard DPJ, Paul NLM, Li L, Mehta Z, Rothwell PM, et al. Recent time
531		trends in incidence, outcome and premorbid treatment of atrial fibrillation-related
532		stroke and other embolic vascular events: a population-based study. J Neurol
533		Neurosurg Psychiatry. 2015/10/20. 2017;88: 12-18. doi:10.1136/jnnp-2015-311947
534	2.	NICE. Atrial fibrillation: management (Aug 2014 update) [Internet]. 2014.
535	3.	Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk
536		Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using
537		a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation.
538		Chest. 2010;137: 263–272. doi:10.1378/chest.09-1584
539	4.	Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A Novel User-
540		Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients
541		With Atrial Fibrillation: The Euro Heart Survey. Chest. 2010;138: 1093–1100.
542		doi:10.1378/chest.10-0134
543	5.	Cowan C, Healicon R, Robson I, Long WR, Barrett J, Fay M, et al. The use of
544		anticoagulants in the management of atrial fibrillation among general practices in
545		England. Heart. 2013;99: 1166-1172. doi:10.1136/heartjnl-2012-303472
546	6.	Campbell Cowan J, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of
547		hospitalized atrial fibrillation-related stroke in England and its association with uptake
548		of oral anticoagulation. Eur Heart J. 2018; doi:10.1093/eurheartj/ehy411
549	7.	Lacoin L, Lumley M, Ridha E, Pereira M, McDonald L, Ramagopalan S, et al.
550		Evolving landscape of stroke prevention in atrial fibrillation within the UK between
551		2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open. 2017;7:

552 e015363. doi:10.1136/bmjopen-2016-015363

- 553 8. Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GYH. Risk of stroke and
- oral anticoagulant use in atrial fibrillation: A cross-sectional survey. Br J Gen Pract.
- 555 2012; doi:10.3399/bjgp12X656856
- 556 9. Hemingway H, Asselbergs FW, Danesh J, Dobson R, Maniadakis N, Maggioni A, et
- al. Big data from electronic health records for early and late translational
- 558 cardiovascular research: challenges and potential. Eur Heart J. 2017;39: 1481–1495.
- 559 doi:10.1093/eurheartj/ehx487
- 560 10. Kharrazi H, Anzaldi LJ, Hernandez L, Davison A, Boyd CM, Leff B, et al. The Value
- 561 of Unstructured Electronic Health Record Data in Geriatric Syndrome Case
- 562 Identification. J Am Geriatr Soc. 2018;66: 1499–1507. doi:10.1111/jgs.15411
- 563 11. Jackson R, Kartoglu I, Stringer C, Gorrell G, Roberts A, Song X, et al. CogStack -
- 564 Experiences of deploying integrated information retrieval and extraction services in a
- 565 large National Health Service Foundation Trust hospital. BMC Med Inform Decis
- 566 Mak. 2018; doi:10.1186/s12911-018-0623-9
- 567 12. CogStack. CogStack Pipeline [Internet]. 2019. Available:
- 568 https://github.com/CogStack/CogStack-Pipeline
- 13. Wu H, Toti G, Morley KI, Ibrahim ZM, Folarin A, Jackson R, et al. SemEHR: A
- 570 general-purpose semantic search system to surface semantic data from clinical notes
- 571 for tailored care, trial recruitment, and clinical research. J Am Med Informatics Assoc.
- 572 2018; doi:10.1093/JAMIA/OCX160
- 573 14. Wu H. CogStack-SemEHR [Internet]. p. 2019.
- 574 15. Wang S V, Rogers JR, Jin Y, Fischer MA, Bates DW. Use of electronic healthcare

575		records to identify complex patients with atrial fibrillation for targeted intervention. J
576		Am Med Informatics Assoc. 2016;24: 339–344. doi:10.1093/jamia/ocw082
577	16.	Grouin C, Deléger L, Rosier A, Temal L, Dameron O, Van Hille P, et al. Automatic
578		computation of CHA2DS2-VASc score: information extraction from clinical texts for
579		thromboembolism risk assessment. AMIA . Annu Symp proceedings AMIA Symp.
580		2011;
581	17.	Rosier A, Mabo P, Temal L, Van Hille P, Dameron O, Deléger L, et al. Personalized
582		and automated remote monitoring of atrial fibrillation. Europace. 2016;
583		doi:10.1093/europace/euv234
584	18.	U.S. National Library of Medicine. Unified Medical Language System (UMLS)
585		[Internet]. Available: https://www.nlm.nih.gov/research/umls/
586	19.	Köhler S, Carmody L, Vasilevsky N, Jacobsen JOB, Danis D, Gourdine JP, et al.
587		Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources.
588		Nucleic Acids Res. 2019; doi:10.1093/nar/gky1105
589	20.	Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development
590		and validation of a Hospital Frailty Risk Score focusing on older people in acute care
591		settings using electronic hospital records: an observational study. Lancet. 2018;
592		doi:10.1016/S0140-6736(18)30668-8
593	21.	Whetzel PL, Noy NF, Shah NH, Alexander PR, Nyulas C, Tudorache T, et al.
594		BioPortal: Enhanced functionality via new Web services from the National Center for
595		Biomedical Ontology to access and use ontologies in software applications. Nucleic
596		Acids Res. 2011; doi:10.1093/nar/gkr469
597	22.	Kreimeyer K, Foster M, Pandey A, Arya N, Halford G, Jones SF, et al. Natural

598		language processing systems for capturing and standardizing unstructured clinical
599		information: A systematic review. Journal of Biomedical Informatics. 2017.
600		doi:10.1016/j.jbi.2017.07.012
601	23.	Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, et al. Alert-based
602		computerized decision support for high-risk hospitalized patients with atrial fibrillation

- not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). Eur Heart 603 J. 2019; doi:10.1093/eurheartj/ehz385 604
- 605 24. Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot J-M, et al. Underuse of Oral
- Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in 606
- France: Comparisons of Resident Characteristics and Physician Attitude. J Am Geriatr 607 Soc. 2015;63: 71–76. doi:10.1111/jgs.13200

- 25. Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Kha Nguyen JN, Viet-Quoc 609
- 610 Nguyen P, et al. The Effect of Bleeding Risk and Frailty Status on Anticoagulation
- Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. Can J 611
- Cardiol. 2016;32: 169–176. doi:10.1016/j.cjca.2015.05.012 612
- Pilotto A, Gallina P, Copetti M, Pilotto A, Marcato F, Mello AM, et al. Warfarin 613 26.
- Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial 614
- Fibrillation: A Retrospective Observational Study. J Am Geriatr Soc. 2016/06/13. 615
- 2016;64: 1416–1424. doi:10.1111/jgs.14221 616
- 27. Faxon DP, Burgess A. Cardiovascular Registries: Too Much of Good Thing? 617
- Circulation. Cardiovascular interventions. United States; 2016. p. e003866. 618
- doi:10.1161/CIRCINTERVENTIONS.116.003866 619
- 28. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, et al. Influence of 620
- Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. J 621

622		Am Coll Cardiol. 2017;69: 2475–2484. doi:https://doi.org/10.1016/j.jacc.2017.03.540
623	29.	Fosbol EL, Holmes DN, Piccini JP, Thomas L, Reiffel JA, Mills RM, et al. Provider
624		specialty and atrial fibrillation treatment strategies in United States community
625		practice: findings from the ORBIT-AF registry. J Am Heart Assoc. 2013;2: e000110-
626		e000110. doi:10.1161/JAHA.113.000110
627	30.	Topol EJ. High-performance medicine: the convergence of human and artificial
628		intelligence. Nat Med. 2019;25: 44-56. doi:10.1038/s41591-018-0300-7
629		
630		
631		

632 Supporting information

S1 Table. Definition of HAS-BLED and CHA2DS2-VASc as used in this study. Age and
gender are included directly from electronic health record data. The agreed terms under
"include" and "exclude" headings were used by clinical experts to calculate each score
manually. The lists of UMLS concepts for each component were derived automatically and
used by the NLP scoring algorithm.

639 S2 Table. Performance of the NLP pipeline for each component of CHA₂DS₂-VASc and
640 HAS-BLED. Cases were considered positive if at least one manual rater marked as positive.
641 The agreement between the two manual raters is shown as "agreement between raters".

642

643	S3 Table. Total score and component score for CHA2DS2-VASc and HAS-BLED. Each
644	row represents a single patient identified only by row number ("Patient" column).
645	
646	
647	
648	
649	
650	
651	
652	

653 Figure 1.



Figure 2.







Discharge location





678 Figure 3.



